This bill reauthorizes and expands the Accelerating Access to Critical Therapies for ALS Act through 2031, extending funding for research into treatments for amyotrophic lateral sclerosis. It requires drug manufacturers to share interim clinical trial data with the FDA to better assess the progress of investigational drugs and clarifies that phase 3 clinical trial definitions include combined phase 2/3 trials and planned trials not yet enrolling participants. The legislation also mandates the FDA to publish an updated five-year action plan for ALS and other rare neurodegenerative diseases, including resource needs and coordination strategies with broader disease communities. Additionally, the bill requires the Government Accountability Office to submit a report on the program's implementation four years after enactment.
The Main Street Capital Access Act reduces regulatory burdens for smaller banks, particularly those with less than $10 billion in assets. Key provisions include a 3-year phase-in period for new banks to meet capital requirements, lower leverage ratio requirements for rural banks (7.5% for the first 2 years), and a 30-day review process for business plan deviations. The bill also establishes an Office of Independent Examination Review, sets specific timelines for examinations (270 days) and reports (90 days), and creates a "least cost exception" for bank resolutions to prevent excessive concentration of the banking system. These changes aim to promote new bank formation, improve regulatory efficiency, and support community banking while maintaining financial stability.
This bill reauthorizes and updates the American Battlefield Protection Program through 2036, extending funding for battlefield preservation grants. It increases the maximum grant percentage for battlefield interpretation projects from 50% to 75% and sets $2 million annually for battlefield restoration grants through 2036. The bill also requires the National Park Service to study French and Indian War (1754-1763) and Mexican-American War (1846-1848) sites across the U.S., assessing their significance, threats, and preservation options. These studies must involve state governors, tribal governments, local officials, and historic preservation groups, with a final report due to Congress within two years of funding. The program directly affects federal, state, tribal, and local entities managing historic battlefields.
HR 6330, the Federal Relocation Payment Improvement Act, allows federal agencies to pay eligible employees a single lump-sum payment instead of the standard relocation reimbursements when employees move for government work. This directly affects federal employees who relocate for agency assignments, giving agencies flexibility to choose between the lump sum or existing payment methods. The bill requires the General Services Administration to create regulations detailing when agencies may use lump sums, how to calculate the amount, and the process for employees to dispute claims or appeal decisions to the Civilian Board of Contract Appeals. It does not change relocation eligibility but modifies the payment structure and dispute procedures.
This bill names the Department of Veterans Affairs multispecialty clinic at 1263 Cobb Parkway NW in Marietta, Georgia, as the "Colonel Michael H. Boyce Department of Veterans Affairs Multispecialty Clinic." It is a ceremonial resolution with no policy changes or funding impacts - it solely updates the facility's official designation in government records. The clinic itself remains unchanged, and the bill does not alter services, funding, or operations for veterans.
The AADAPT Act reauthorizes and expands Project ECHO grants to improve Alzheimer’s and dementia care through technology-enabled training. It specifically funds grants for healthcare providers in rural, frontier, or medically underserved areas to enhance early diagnosis, quality care, and provider retention for dementia patients. The bill authorizes $1 million annually (2027-2032) for these dementia-focused training programs, requiring funds to supplement - not replace - existing resources. This directly supports primary care providers licensed to serve underserved communities, using collaborative online learning to address care gaps.
HR 3029, the Nucleic Acid Standards for Biosecurity Act, directs the National Institute of Standards and Technology (NIST) to develop new screening standards for synthetic DNA and RNA production to prevent misuse. It requires NIST to research improved testing accuracy, security protocols for sequence databases, and technical guidance for screening tools, with a stakeholder consortium including industry and researchers to set priorities. The bill authorizes $5 million annually (2026-2030) for NIST to carry out this work and mandates a report to Congress within 18 months of the first consortium meeting. This directly affects biotechnology companies, research institutions, and labs producing synthetic genetic materials by establishing new biosecurity screening requirements.
HR 2821, the FDA Modernization Act 3.0, requires the FDA to update regulatory language within one year of enactment. It directs the agency to replace all references to "animal tests" with "nonclinical tests" in 22 specific sections of the Code of Federal Regulations related to drug development and approval processes. The bill also adds a definition for "nonclinical test" into relevant FDA regulations to align with prior legislative changes. This update applies directly to pharmaceutical manufacturers and FDA reviewers who follow these regulatory guidelines during drug development. The changes aim to modernize terminology without altering current testing requirements.
HR 2715, the *Destruction of Hazardous Imports Act*, expands the authority to destroy imported goods that pose public health risks. It amends the Federal Food, Drug, and Cosmetic Act to allow the Secretary of Health and Human Services to order the destruction of any refused import (not just drugs or devices) if it presents a significant health concern. The bill also prohibits the unauthorized movement, sale, or export of such refused goods. These changes apply to importers of hazardous refused articles 180 days after enactment, with the FDA required to finalize implementing regulations within 90 days.
HR 2306 extends the Adams Memorial Commission's authority until 2032 and authorizes $50 million in federal funds for the memorial, requiring a 1:1 non-federal match and limiting administrative costs to 4% of federal funds. It updates location rules to allow the memorial within a designated area mapped by the Commission. The bill primarily affects the Adams Memorial Commission and entities contributing to the memorial's funding. It makes no new policy changes but adjusts procedural timelines and funding requirements for an existing commemorative project.
HR 2913, the Ukraine Support Act, provides comprehensive U.S. support for Ukraine in response to Russia's invasion. The bill authorizes security assistance including lend-lease authority for military equipment, establishes a Ukraine Reconstruction Trust Fund for economic recovery, and imposes new sanctions targeting Russian financial institutions, oil companies, and government officials. It also includes provisions to counter Russian disinformation, support Radio Free Europe, and address the kidnapping of Ukrainian children. The legislation directly affects U.S. foreign policy, Ukraine's defense capabilities, and Russia's access to international financial systems. The act aims to strengthen Ukraine's sovereignty while holding Russia accountable for its actions.
This resolution honors the life and legacy of the late Senator Lindsey Olin Graham from South Carolina. It formally acknowledges his extensive career in the military, state government, and Congress, noting his service as a Senator and his roles as Chairman of the Judiciary and Budget committees. The Senate expresses its sorrow over his death and requests that this tribute be shared with the House of Representatives and Graham's family.
